Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas

Taishi Nakase[1], Stephen S. Francis[2,3,4], Geno Guerra[2], Qingyu Zhao[5], Linda Kachuri[1,6]

Affiliations:
1. Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA
2. Department of Neurological Surgery, University of California San Francisco, San Francisco, CA
3. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
4. Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA
5. Department of Radiology, Weill Cornell Medicine, New York, NY
6. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

Corresponding author:
Linda Kachuri, PhD
Department of Epidemiology and Population Health
Stanford University School of Medicine
300 Pasteur Drive, Alway Building, Room 105A, Stanford, CA 94305
Email: lkachuri@stanford.edu
Telephone: (650) 723-9384

ABSTRACT

The molecular profiling of gliomas for isocitrate dehydrogenase (*IDH*) mutations currently relies on resected tumor samples, highlighting the need for non-invasive, preoperative biomarkers. We investigated the integration of glioma polygenic risk scores (PRS) and radiomic features for prediction of *IDH* mutation status. The elastic net classifier used 256 radiomic features, a glioma PRS and demographic information in 159 glioma cases. The integration of glioma PRS with radiomics increased the area under the receiver operating characteristic curve (AUC) for distinguishing IDH-wildtype vs. IDH-mutant glioma from 0.824 to 0.890 ($P_{\Delta AUC}$=0.0016). Incorporating age at diagnosis and sex further improved the classifier (AUC=0.920). Patients predicted to have IDH-mutant vs. IDH-wildtype tumors had significantly lower mortality risk (hazard ratio (HR)=0.27, 95% CI: 0.14-0.51, P=6.3×10^{-5}), comparable to prognostic trajectories for biopsy-confirmed *IDH* status. The augmentation imaging-based classifiers with genetic risk profiles may help delineate molecular subtypes and improve the timely, non-invasive clinical assessment of glioma patients.

INTRODUCTION

Gliomas are the most common primary malignant brain tumors in adults[1]. These neoplasms encompass multiple subtypes with distinct somatic mutations that delineate different clinical trajectories[2]. Although glioma classifications continue to evolve, several key features have been used to define molecular subtypes since 2016: isocitrate dehydrogenase 1 and 2 mutations (collectively referred to as *IDH* mutations), chromosome 1p and 19q co-deletion, and *TERT* promoter mutations[2–4]. The 2021 World Health Organization (WHO) glioma classification guidelines use these tumor molecular features to define three glioma subtypes[5]: tumors without *IDH* mutation (IDH-wildtype glioblastomas), tumors with *IDH* mutation and an unbalanced translocation between chromosomes 1 and 19 (IDH-mutant 1p19q co-deleted oligodendrogliomas), and IDH-mutant tumors without 1p19q co-deletion (IDH-mutant astrocytomas). IDH-wildtype glioblastomas (GBM) are more aggressive, have fewer treatment options and are associated with significantly shorter overall survival than IDH-mutant gliomas[2,6]. The early establishment of a molecular diagnosis for gliomas is important to predict tumor behavior and guide treatment of individual patients[7–9].

Currently, the classification of gliomas into prognostically significant subtypes is based on histopathological and molecular assessment of tissue samples obtained from biopsy or resection. Therefore, the evaluation of treatment options and prognostication are often delayed until after surgery, which carries the risk of permanent operative complications or may not be readily accessible in low-resource settings. Recent efforts have been aimed at using noninvasive procedures such as imaging[10–13] and germline genotyping[14,15] to provide insight into the presence or absence of clinically relevant somatic mutations (e.g. *IDH* mutation) prior to surgical interventions. By providing timely insight into the tumor molecular profile, these noninvasive tools may complement the standard histopathological assessment of surgical specimens to expedite treatment decisions and better inform patient management.

Major advances have been made in the use of tumor radiographic features obtained from preoperative imaging data to classify gliomas into molecular subtypes. Earlier applications of machine learning (ML) to imaging data for tumor classification used textural analysis approaches or rule-based systems such as VASARI[16,17]. Since these approaches rely on manual feature selection, research efforts have since focused on the development of deep learning models such as convolutional neural networks (CNNs) that automatically extract features from complex images[11–13]. Recent CNN-based models for glioma classification have shown promising results, with model predictions recapitulating prognostic outcomes expected for different molecular subtypes. However, previous studies of imaging features have not accounted for other known clinical and genetic indicators of subtype-specific glioma risk.

Genome-wide association studies (GWAS) for glioma have shown that inherited genetic variation influences disease risk and that different molecular subtypes are associated with distinct genetic risk loci[18,19]. Polygenic risk scores (PRS), which aggregate the effects of risk alleles across the genome to provide a personalized genetic susceptibility profile[20], have been shown to predict subtype-specific glioma risk and accurately distinguish among molecular subtypes[14,15]. Since gliomas sometimes present with non-characteristic radiographic features (e.g. IDH-wildtype non-enhancing tumors)[13], inherited genetic variation could offer an additional indicator of malignancy risk independent of radiomic features that might improve the performance of imaging-based classification models.

In this study, we integrated radiomic features extracted from pre-operative multimodal magnetic resonance imaging (MRI) scans with germline PRS profiles to classify gliomas according to *IDH* mutation status. Using the developed classification model, we also identify predictive features in subtype discrimination and assess their clinical significance.

METHODS

Study population

The analysis group consisted of 768 glioma cases (384 IDH-wildtype, 384 IDH-mutant) with available tumor molecular data from The Cancer Genome Atlas (TCGA). TCGA is a public data repository for de-identified tumor samples from consented patients (https://www.cancer.gov/tcga). Cases were genotyped on the Affymetrix 6.0 array and imputed with the TOPMed reference panel, with standard quality control procedures as previously described[14,21]. Briefly, SNPs with a call rate <95% were excluded along with those at a low minor allele frequency (MAF<0.005) or showing significant deviation from the Hardy-Weinberg equilibrium ($P<10^{-6}$). Analyses were also restricted to individuals of predominantly European ancestry. Among the 768 glioma cases with genotyping data, 159 cases (82 IDH-wildtype, 77 IDH-mutant) also had available radiomic data extracted from pre-operative multimodal MRI scans provided by The Cancer Imaging Archive[22–24]. As described in Bakas et al[22], T1-weighted pre-contrast (T1), T1-weighted post-contrast (T1-Gd), T2 and T2-FLAIR scans of each patient underwent standard pre-processing including registration, resampling and skull stripping, followed by computer-aided assignment of segmentation labels to tumor sub-regions (e.g. peritumoral edema). Computer-aided segmentation labels were then manually-revised by a neuroradiologist. Based on the assigned labels of each tumor sub-region, a panel of radiomic features were extracted, which included intensity, volumetric, morphologic, histogram, textural, spatial and tumor diffusion parameters.

Genetic data preprocessing and feature extraction

An overview of the study design and analysis is provided in **Figure 1**. Using individual-level genotyping data, we fit four previously developed subtype-specific PRS for each patient in TCGA, as described in Nakase et al[14]. Briefly, the GBM PRS and the non-GBM PRS were trained using summary statistics from a GWAS of 10346 cases (5395 GBM, 4466 non-GBM) and 14,687 controls, while PRS for molecular subtypes were developed using GWAS results from 2632 cases (1115 IDH-wildtype, 699 IDH-mutant) and 2445 controls[14,18,19].

For each individual, each subtype-specific PRS was converted to a standardized z-score based on the in-sample TCGA distribution. To adjust for population stratification, we regressed out the effects of the first 10 genetic ancestry principal components and used the residualized z-scores for each PRS in subsequent processing. Next, we fit a logistic regression model with *IDH* mutation status as the outcome and the four residualized PRS features as the explanatory variables on the subset of 609 patients without radiomic data. This model was then applied to the 159 patients with both radiomic and germline genetic data to extract a new composite PRS feature based on the weighted effect of each subtype-specific PRS.

Radiomic data preprocessing and feature extraction

Of the 723 radiomic features, 467 were not available for all cases and were excluded from the analysis. For each of the remaining 256 radiomic features, we calculated its standardized z-score. We assessed for potential confounding by age, sex and brain volume (excluding skeletal structures) by calculating the Pearson correlation between the standardized z-score of each radiomic feature and each factor. For each feature that was significantly correlated with age, sex or brain volume (P<0.05), residualization was performed to omit the effect of these factors[25].

Model development and evaluation

We used an elastic net to classify glioma cases according to *IDH* mutation status in the subset of the TCGA dataset with both radiomic and germline genetic information. In addition to the single composite PRS feature and the 256 radiomic features, age at diagnosis and sex were used as model inputs. To obtain unbiased estimates of model performance in our single TCGA cohort, we performed nested cross-validation (CV). An overview of the nested CV procedure is provided in **Supplementary Figure 1**. Briefly,

the whole dataset was partitioned into 5 outer CV folds with each fold divided into a training set (80%)
and a hold-out test set (20%). For each outer training fold, we performed 5-fold CV to tune the
hyperparameters and then fitted the tuned model to the whole training fold. The fitted model with the best
hyperparameter configuration was then applied to the corresponding hold-out test set. Model
performance was evaluated across the predictions of the concatenated hold-out test sets of each of the 5
outer CV folds. We used standard logistic regression for the demographics only (age at diagnosis and
sex) and PRS only models. Classification performance was quantified using accuracy, precision, recall,
F1-score and area under the receiver operating characteristic curve (AUC). The difference in AUC
between models was assessed using DeLong's test. Feature importance was quantified using the
distribution of weights across the 5 outer CV folds. Features whose mean weights were significantly
different from zero based on a one-sample t-test (P<0.05) were regarded as predictive features.

Survival analysis

We examined how well the integrated genetic and radiomic IDH classifier predicted overall survival.
Follow-up time was calculated from date of diagnosis to death or end of follow-up. Kaplan-Meier curves
were used to visually compare survival trajectories based on predicted IDH status. Differences in event
time distributions were assessed using the log rank test. To incorporate covariates, hazard ratios (HR) for
predicted IDH status were estimated using Cox proportional hazards models with adjustment for age at
diagnosis and sex, and stratification by disease grade. In addition to prognostic associations for predicted
IDH status, we also evaluated the association of each feature that was included in the classifier with
overall survival.

RESULTS

Characteristics of study population

Basic summary information of study participants overall and stratified by available genotyping and
radiomic data is provided in **Table 1**. The median age of included cases was 52 years, with more males
(58.5%) than females (41.5%). Overall, we included 384 subjects diagnosed with IDH-wildtype GBM, 235
with IDH-mutant astrocytoma and 147 with IDH-mutant 1p19q-codeleted oligodendroglioma.

IDH classification

We examined the classification performance of different combinations of features for predicting *IDH*
mutation status (**Table 2**). In models limited to features of a single category (i.e. demographics, genetics
or radiomics), we found that the radiomics-based model was the most predictive for *IDH* status
classification. The radiomics-based model yielded higher AUC (0.824, 95% confidence interval (CI):
0.755-0.894) than the composite PRS model (0.702, 95% CI: 0.622-0.782, $P_{\Delta AUC}=0.039$) and the
demographics only model (0.751, 95% CI: 0.673-0.829, $P_{\Delta AUC}=0.19$). Radiomics features also exhibited
improved accuracy (0.774), recall (0.779) and F1-score (0.769) compared to the other single-category
models.

Next, we assessed whether germline genetics, demographics, and radiomics might contribute orthogonal
information towards *IDH* status classification (**Table 2**). The elastic net model that included both PRS and
radiomic features achieved significantly improved performance compared to the radiomics-based model,
with an AUC of 0.890 (95% CI: 0.837-0.943, $P_{\Delta AUC}=0.0016$). Model performance was further improved by
adding age at diagnosis and sex to the radiomics features (AUC=0.906, 95% CI: 0.856-0.955). Overall,
the integrated model that included demographics, radiomics, and PRS features achieved the highest AUC
(0.920, 95% CI: 0.876-0.964), accuracy (0.849), recall (0.844) and F1-score (0.844). Repeating the
nested cross-validation procedure for 500 random training/testing splits showed that the inclusion of

genetic and demographic features in the radiomics-based model increased classification performance
(**Figure 2**). The AUC distribution of the full integrated model achieved a median of 0.937 (interquartile
range (IQR)=0.920-0.937) compared to a median of 0.882 (IQR=0.871-0.893) for the combined radiomics
and genetics model and a median of 0.838 (IQR=0.824-0.851) for the radiomics-only model.

In sensitivity analyses, we assessed the relative performance of the various models using radiomic
features that were not adjusted for confounding factors such as age, sex and brain volume
(**Supplementary Table 1**). The radiomics model showed significantly higher AUC (0.887, 95% CI: 0.833-
0.942) than both the composite PRS feature model (AUC=0.702, $P_{\Delta AUC}=5.7\times10^{-4}$) and the demographics-
only model (AUC=0.751, $P_{\Delta AUC}=0.0034$). Adding germline genetics to radiomics features increased
accuracy (0.843 vs. 0.830), F1-score (0.832 vs. 0.814) and AUC (0.920, 95% CI: 0.878-0.962,
$P_{\Delta AUC}=0.018$). The full integrated model that included age at diagnosis and sex had the best overall
classification performance with an accuracy of 0.868, F1-score of 0.863, and an AUC=0.920 (95% CI:
0.878-0.963). When we repeated the nested cross-validation procedure for 500 iterations
(**Supplementary Figure 2**), the full integrated model showed a higher median AUC (0.927, IQR=0.927-
0.934) than the combined radiomics and genetics model (AUC=0.920, IQR=0.911-0.927) and the
radiomics-only model (AUC=0.881, IQR=0.891-0.900).

Feature importance

Overall, 40 out of the 256 features had non-zero cumulative weights in the elastic net model that included
all available features (**Figure 3A**). Of those 40 features, 8 were significantly predictive of *IDH* mutation
status: age at diagnosis, germline genetic susceptibility, the ratio of the enhancing tumor (ET) volume to
whole tumor (WT) volume, heterogeneity of the non-enhancing tumor (NET), the percentage of the tumor
core (TC) in the frontal lobe, the ratio of the NET volume to the WT volume, the ratio of the ET to the TC
volume and the ratio of the NET volume to the TC volume (**Figure 3B**). Various texture-based radiomic
features calculated from gray-level intensities also had non-zero cumulative weights in the elastic net
model, although their mean weights were not significantly different from zero (**Figure 3A**). Compared to
IDH-wildtype tumors, IDH-mutant tumors were generally diagnosed at an earlier age, had minimal areas
of enhancement and more often developed in the frontal lobe (**Figure 3B**).

Survival analysis

Patients predicted to have IDH-mutant gliomas showed significantly improved survival compared to
patients predicted to have IDH-wildtype gliomas (HR=0.27, 95% CI: 0.14-0.51, $P=6.3\times10^{-5}$; **Table 3**). The
difference in median survival between IDH-mutant and IDH-wildtype predictions was 72.7 months
($P=2.1\times10^{-11}$; **Figure 4B**). Median survival time for patients predicted to have IDH-mutant (87.4 months)
vs. IDH-wildtype tumors (14.7 months) was similar to patients with biopsy-confirmed IDH-mutant (87.4
months) vs. IDH-wildtype tumors (14.3 months; **Figure 4A**). Among grades II or III gliomas, patients
predicted to have IDH-mutant tumors had significantly lower mortality risk than patients predicted to have
IDH-wildtype tumors (HR=0.28, 95% CI: 0.11-0.69, P=0.0062; **Figure 4D**), which was comparable to the
survival difference observed for *IDH* mutation status based on postoperative molecular profiling (HR=0.19,
95% CI: 0.07-0.53, P=0.0015; **Figure 4C**). For grade IV gliomas, the median survival difference between
patients predicted to have IDH-mutant tumors compared to patients predicted to have IDH-wildtype
tumors was attenuated at 7.4 months (P=0.30; **Figure 4D**). Similar differences in median survival were
observed when we compared patients with grade IV gliomas based on biopsy-confirmed *IDH* mutation
status (10.5 months, P=0.087; **Figure 4C**).

Of the 40 features that had non-zero cumulative weights in the integrated *IDH* classifier, age at diagnosis
and 23 radiomic features were associated with all-cause mortality at P<0.05 (**Figure 5, Supplementary**
Table 2). Prognostic radiomic features were primarily related to characteristics of the ET and NET regions.

For instance, higher relative enhancing tumor volume (i.e. ET/TC) was associated with a 51% increase in
overall mortality risk (HR=1.51, 95% CI: 1.22-1.86, P=1.2×10^{-4}), while tumors with greater solidity of the
NET had lower mortality risk (HR=0.61, 95% CI: 0.49-0.77, P=3.1×10^{-5}).

DISCUSSION

In this case study, we integrated radiomic features extracted from pre-operative MRI scans, a composite
PRS for IDH-mutant glioma and demographic features such as age at diagnosis and sex to classify
gliomas according to *IDH* mutation status. Previous models used to classify gliomas into clinically-relevant
molecular subtypes have relied on either radiomic[11–13] or germline genetic features[14,15] and have not
assessed whether inherited glioma susceptibility may assist in the classification of gliomas that present
with non-characteristic radiographic properties. With larger glioma GWAS yielding greater insight into
subtype-specific glioma risk, we sought to leverage the unique germline genetic signatures of glioma
subtypes[18,19] in integrative classification models to potentially improve preoperative prognostication and
treatment algorithms. We found that the inclusion of diverse features extracted from multiple
complementary sources may improve model accuracy. The elastic net model that included all available
features achieved the best overall classification performance, with an AUC of 0.920 and accuracy of
0.849 on nested cross-validation. These results are consistent with observations for other cancers such
as thyroid cancer, where polygenic risk scores improved imaging-based classifiers of malignancy risk[26].
We also found that age at diagnosis and germline genetic susceptibility were among the most predictive
features along with volume of ET and NET, and the percentage of the TC in the frontal lobe. Critically, our
predicted subtype labels were clinically significant such that patients predicted to have IDH-wildtype
glioma showed significantly higher mortality risk than patients predicted to have IDH-mutant glioma.

Tumor molecular markers, especially *IDH* mutation status, have critical implications for prognosis[7,8] and
treatment response[9]. Currently, the classification of gliomas into clinically-relevant subtypes relies on
molecular profiling of surgical tumor specimens. This often delays the evaluation of non-surgical treatment
options until after invasive surgery, thereby forgoing the opportunity for neoadjuvant therapy and
postponing the future use of adjuvant chemoradiotherapy. While combined temozolomide and
radiotherapy remains the standard of care for IDH-wildtype glioblastoma[27], Vorasenib, an inhibitor of *IDH1*
and *IDH2* enzymes, was recently shown to improve progression-free survival in patients with IDH-mutant
glioma[28]. Although the optimal timing of Vorasenib treatment has not been studied, when provided earlier
in the disease course, it might delay subsequent interventions in patients with low-grade glioma and
improve quality of life. Our study provides further support for the use of noninvasive tools such as
genotyping and imaging to accurately predict *IDH* mutation status in gliomas prior to surgical intervention,
and thus potentially identify those patients suitable for neoadjuvant therapy with *IDH* inhibitors. However,
the added value of these ML approaches in patient management will require careful evaluation of their
potential risks and contextualization in different clinical settings.

This work has several limitations. First, statistical power for model comparisons and survival analyses
was limited since only 21% of TCGA participants had both radiomic and genotyping data available.
Second, while nested cross-validation provides some robustness by evaluating performance based on in-
sample hold-out subsets, external populations from different clinical centers are required for an unbiased
and more informative evaluation. Lastly, our analyses focused on *IDH* mutation status, and we did not
consider more refined molecular subtypes based on additional features, such as 1p19q codeletion, *TERT*
promoter mutations and *EGFR* amplification due to limited sample size. However, of the currently used
somatic mutations, *IDH* status is the most prognostically significant[2,4].

In this analysis, we used a predefined set of radiomic features from imaging data with manually-revised
segmentation labels[22]. Several recent studies have developed end-to-end CNN-based models that

automatically learn imaging features and perform both tumor segmentation and classification within a single framework[11–13]. These multi-task deep learning approaches do not rely on manual delineation of tumor regions, reduce computational burden and require minimal input from health care providers once trained, thereby facilitating their integration into existing neuro-oncology workflows. However, CNN approaches are mostly image-intensity based and do not account for other types of features that might be informative for subtype discrimination, which may limit their performance, especially in patients with non-characteristic radiographic findings. As individual-level genotyping on larger cohorts of glioma patients become available, CNN-based models that incorporate germline genetic and demographic features can be trained using a late-fusion strategy[13,29].

This work has several important strengths. Our study applies genome-wide PRS for glioma that were previously developed using the largest available collection of glioma GWAS data and have been shown to accurately estimate subtype-specific glioma risk in multiple independent populations[14]. We also leverage genetic data without corresponding radiomic data in TCGA to generate a composite PRS feature that reflects the joint effects of multiple subtype-specific PRS on the risk of IDH-mutant glioma. In addition to evaluating classification of *IDH* mutation status, we also assessed the degree to which our predicted molecular subtypes delineated survival trajectories, which is informative for evaluating the potential utility of preoperative glioma classification models in clinical practice.

In summary, this the first study to demonstrate that integration of genetic risk profiles with MRI-based radiomic features significantly improves *IDH* status classification of glioma cases in TCGA. Given the available data, our case study helps motivate future research on multimodal glioma classification models. Although this work underscores the potential added value of multiple complementary features in glioma subtype classification, an assessment of the clinical utility of this integrated approach will require further testing in larger cohorts using different imaging-based ML algorithms.

REFERENCES

1. Ostrom, Q. T. *et al.* CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020. *Neuro-oncology (Charlottesville, Va.)* **25**, iv1– iv99 (2023).

2. Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and Molecular Epidemiology of Adult Diffuse Glioma. *Nature reviews. Neurology* **15**, 405–417 (2019).

3. The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med* **372**, 2481–2498 (2015).

4. Eckel-Passow, J. E. *et al.* Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *The New England journal of medicine* **372**, 2499–2508 (2015).

5. Louis, D. N. *et al.* The 2021 WHO classification of tumors of the central nervous system: A summary. *Neuro-oncology (Charlottesville, Va.)* **23**, 1231–1251 (2021).

6. Poon, M. T. C., Sudlow, C. L. M., Figueroa, J. D. & Brennan, P. M. Longer-term ($\geq$ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. *Scientific Reports* **10**, 11622 (2020).

7. Aoki, K. *et al.* Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. *Neuro-oncology (Charlottesville, Va.)* **20**, 66–77 (2018).

8. Pekmezci, M. *et al.* Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. *Acta neuropathologica* **133**, 1001–1016 (2017).

9. Miller, J. J., Shih, H. A., Andronesi, O. C. & Cahill, D. P. Isocitrate dehydrogenase mutant glioma: Evolving clinical and therapeutic implications. *Cancer* **123**, 4535–4546 (2017).

10. Peng, H. *et al.* Predicting Isocitrate Dehydrogenase (**IDH)** Mutation Status in Gliomas Using Multiparameter **MRI** Radiomics Features. *Magnetic Resonance Imaging* **53**, 1399–1407 (2021).

11. Chang, P. *et al.* Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas. *AJNR Am J Neuroradiol* **39**, 1201–1207 (2018).

12. Choi, Y. S. *et al.* Fully automated hybrid approach to predict the *IDH* mutation status of gliomas via deep learning and radiomics. *Neuro-Oncology* **23**, 304–313 (2021).

13. Chakrabarty, S., LaMontagne, P., Shimony, J., Marcus, D. S. & Sotiras, A. MRI-based classification of

IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional

neural network. *Neuro-Oncology Advances* **5**, vdad023 (2023).

14. Nakase, T. *et al.* Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular

Subtypes. *Neuro-Oncology* noae112 (2024) doi:10.1093/neuonc/noae112.

15. Eckel-Passow, J. E. *et al.* Using germline variants to estimate glioma and subtype risks. *Neuro-*

oncology **21**, 451–461 (2019).

16. Zhou, H. *et al.* MRI features predict survival and molecular markers in diffuse lower-grade gliomas.

Neuro-Oncology **19**, 862–870 (2017).

17. Li, Y. *et al.* Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade,

IDH Mutation, and 1p/19q Codeletion. *Cancers* **14**, 1778 (2022).

18. Melin, B. S. *et al.* Genome-wide association study of glioma subtypes identifies specific differences in

genetic susceptibility to glioblastoma and non-glioblastoma tumors. *Nature genetics* **49**, 789–794

(2017).

19. Eckel-Passow, J. E. *et al.* Adult diffuse glioma GWAS by molecular subtype identifies variants in

D2HGDH and FAM20C. *Neuro-oncology (Charlottesville, Va.)* **22**, 1602–1613 (2020).

20. Choi, S. W., Mak, T. S.-H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic risk score

analyses. *Nat Protoc* **15**, 2759–2772 (2020).

21. Guerra, G. *et al.* The immunogenetics of viral antigen response is associated with subtype-specific

glioma risk and survival. *The American Journal of Human Genetics* **109**, 1105–1116 (2022).

22. Bakas, S. *et al.* Advancing The Cancer Genome Atlas glioma MRI collections with expert

segmentation labels and radiomic features. *Sci Data* **4**, 170117 (2017).

23. Bakas, S. *et al.* Segmentation Labels for the Pre-operative Scans of the TCGA-GBM collection. The

Cancer Imaging Archive https://doi.org/10.7937/K9/TCIA.2017.KLXWJJ1Q (2017).

24. Bakas, S. *et al.* Segmentation Labels for the Pre-operative Scans of the TCGA-LGG collection. The

Cancer Imaging Archive https://doi.org/10.7937/K9/TCIA.2017.GJQ7R0EF (2017).

25. Adeli, E. *et al.* Chained regularization for identifying brain patterns specific to HIV infection.

NeuroImage **183**, 425–437 (2018).

26. Pozdeyev, N. *et al.* Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules

as Benign or Malignant. *The Journal of Clinical Endocrinology & Metabolism* **109**, 402–412 (2024).

27. Stupp, R. *et al.* Effects of radiotherapy with concomitant and adjuvant temozolomide versus

radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the

EORTC-NCIC trial. *The Lancet Oncology* **10**, 459–466 (2009).

28. Mellinghoff, I. K. *et al.* Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. *The New England*

journal of medicine (2023) doi:10.1056/NEJMoa2304194.

29. Zhang, Y. *et al.* A Late Fusion CNN for Digital Matting. in *2019 IEEE/CVF Conference on Computer*

Vision and Pattern Recognition (CVPR) 7461–7470 (IEEE, Long Beach, CA, USA, 2019).

doi:10.1109/CVPR.2019.00765.

AUTHOR CONTRIBUTIONS

Conceptualization of project: TN and LK. Methodology: TN, QZ and LK. Main analyses: TN. Primary data collection and curation: TN, SSF, GG, and LK. Drafting of the manuscript: TN and LK. All authors contributed to, reviewed and approved the final manuscript.

ACKNOWLEDGEMENTS

This study received no funding.

COMPETING INTERESTS

All authors declare no financial or non-financial competing interests.

DATA AVAILABILITY

Genotype data of glioma cases from The Cancer Genome Atlas (TCGA) are available from the Database of Genotypes and Phenotypes (dbGaP) under accession phs000178. Radiomic data of glioma cases from TCGA can be obtained from The Cancer Imaging Archive (https://www.cancerimagingarchive.net)[23,24]. The data required for fitting polygenic risk scores for glioma are available at: https://zenodo.org/records/10790748.

Figure 1: Overview of the study design.

Abbreviations:

PRS	Polygenic risk score
GBM	Glioblastoma
IDH-WT	IDH wildtype
IDH-MT	IDH mutant
GLCM	Grey-level co-occurrence matrix
GLRLM	Gray-level run-length matrix
GLSZM	Gray-level size zone matrix
NGTDM	Neighborhood grey-tone difference matrix

Figure 2: **Distribution of AUC for classification of IDH mutation status from repeated nested cross-**
validation. AUC estimates from 500 random iterations of nested cross-validation were obtained from IDH
classification models using different combinations of features.

Figure 3: Predictive features for IDH status classification. (**A**) Cumulative absolute value of feature
weight in elastic net model that included all available features. Feature weights are normalized by the
maximum value. Only features with normalized cumulative weights greater than 0.01 are shown. (**B**)
Distribution of the significantly predictive features stratified by tumor subtype. Features were defined as
predictive if the mean weight across the folds was significantly different from zero based on a one-sample
t-test (P<0.05). Features are ordered (from left to right) in decreasing importance.

Abbreviations
NET   Non-enhancing tumor
WT   Whole tumor
TC   Tumor core
ET   Enhancing tumor
GLCM   Grey-level co-occurrence matrix
GLSZM   Gray-level size zone matrix
GLRLM   Gray-level run-length matrix
SZLGE   Small zone low gray-level emphasis
SRE   Short run emphasis
NGTDM   Neighborhood grey-tone difference matrix

Figure 4: Kaplan-Meier curves for adult glioma cases with predicted or biopsy-confirmed IDH mutation status. Percent survival distributions for adults with glioma stratified by predicted or biopsy-confirmed IDH mutation status and tumor grade. Differences in event time distributions were assessed using the log rank test. (**A**) IDH mutation status confirmed by molecular profiling of tumor samples. (**B**) IDH mutation status predicted based on integrated elastic net model ("predicted"). (**C**) Biopsy-confirmed IDH mutation status and tumor grade. (**D**) Predicted IDH mutation status and tumor grade.

Figure 5: Feature associations with overall survival. Features used for IDH status classification are examined for association with overall survival using univariate Cox proportional hazards regression. Hazard ratio (HR) and 95% confidence interval (CI) for each feature is presented.

Abbreviations
NET   Non-enhancing tumor
WT   Whole tumor
TC   Tumor core
ET   Enhancing tumor
GLCM   Grey-level co-occurrence matrix
GLSZM   Gray-level size zone matrix
GLRLM   Gray-level run-length matrix
SZLGE   Small zone low gray-level emphasis
SRE   Short run emphasis
NGTDM   Neighborhood grey-tone difference matrix

406 **Table 1: Characteristics of glioma cases in The Cancer Genome Atlas (TCGA).** Characteristics of
407 glioma cases in TCGA are stratified by available germline genetic and radiomic data. For categorical
408 variables, percentage (%) is reported. For quantitative variables, interquartile range (IQR) is reported.

	All Cases	**Genetics Only**	**Genetics and Radiomics**
Median age (IQR)	52 [37-62]	51 [36-62]	54 [41-62]
Sex			
Male	449 (58.5)	362 (59.4)	87 (51.6)
Female	319 (41.5)	247 (40.6)	77 (48.4)
IDH			
Mutated	384 (50.0)	307 (50.4)	77 (48.4)
Wildtype	384 (50.0)	302 (49.6)	82 (51.6)
1p/19q			
Codeleted	147 (19.1)	122 (20.0)	25 (15.7)
Non-codeleted	612 (79.7)	479 (78.7)	133 (83.6)
N/A	9 (1.2)	8 (1.3)	1 (0.6)
Grade			
II	183 (23.8)	144 (23.6)	39 (24.5)
III	212 (27.6)	160 (26.3)	52 (32.7)
IV	327 (42.6)	259 (42.5)	68 (42.8)
N/A	46 (6.0)	46 (7.6)	0 (0.0)
Total	768 (100)	609 (100)	159 (100)

410 **Table 2: Classification performance for IDH mutation status.** Performance metrics are based on
411 classification models for *IDH* mutation status in glioma cases. Models with radiomic features were trained
412 with an elastic net; otherwise, models were trained with logistic regression. Two-sided p-values ($P_{\Delta AUC}$)
413 testing the differences in AUC between the radiomics-based model and other models are based on
414 DeLong's test.

Model features	Accuracy	Precision	Recall	F1-score	AUC (95% CI)		$P_{\Delta AUC}$
Radiomics	0.774	0.759	0.779	0.769	0.824	(0.755, 0.894)	-
Demographics	0.711	0.844	0.494	0.623	0.751	(0.673, 0.829)	0.19
Genetics	0.623	0.631	0.532	0.577	0.702	(0.622, 0.782)	0.039
Genetics + Demographics	0.711	0.804	0.532	0.641	0.775	(0.701, 0.849)	0.38
Radiomics + Demographics	0.830	0.847	0.792	0.819	0.906	(0.856, 0.955)	5.7×10^{-4}
Radiomics + Genetics	0.843	0.851	0.818	0.834	0.890	(0.837, 0.943)	0.0016
Radiomics + Genetics + Demographics	0.849	0.844	0.844	0.844	0.920	(0.876, 0.964)	4.0×10^{-4}

416 **Table 3: Association between IDH mutation status and survival among glioma cases stratified by**
417 **tumor grade.** Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression
418 models adjusted for age at diagnosis and sex with stratification by tumor grade. Predicted subtype labels
419 are based on the full elastic net model with radiomic, germline genetic and demographic features, while
420 ground truth subtype labels are based on molecular profiling of biopsied tumor samples.

	Cases (Deaths)	Median Survival (Months)	HR (95% CI)	P value
Combined				
Predictions				
IDH-wildtype	82 (58)	14.7	1.00	
IDH-mutant	77 (15)	87.4	0.27 (0.14, 0.51)	6.3×10^{-5}
Ground truth				
IDH-wildtype	82 (59)	14.3	1.00	
IDH-mutant	77 (14)	87.4	0.21 (0.11, 0.40)	2.2×10^{-6}
Grade II/III				
Predictions				
IDH-wildtype	22 (11)	18.4	1.00	
IDH-mutant	69 (12)	87.4	0.28 (0.11, 0.69)	0.0062
Ground truth				
IDH-wildtype	19 (10)	18.4	1.00	
IDH-mutant	72 (13)	87.4	0.19 (0.07, 0.53)	0.0015
Grade IV				
Predictions				
IDH-wildtype	60 (47)	13.3	1.00	
IDH-mutant	8 (3)	20.7	0.96 (0.24, 3.89)	0.95
Ground truth				
IDH-wildtype	63 (49)	12.2	1.00	
IDH-mutant	5 (1)	22.7	0.29 (0.04, 2.14)	0.22